Chemotherapy Dosing and Management
Introduction to Chemotherapy Dosing
- The American Society of Clinical Oncology (ASCO) guidelines strongly recommend using actual body weight for calculating chemotherapy doses in obese patients, including those with impaired renal function, with specific dose adjustments based on creatinine clearance rather than weight-based reductions 1, 2
- The American Society of Clinical Oncology (ASCO) guidelines strongly recommend against arbitrary dose reductions or caps based solely on obesity 2
Dosing Calculations
- Actual body weight should be used for calculating Body Surface Area (BSA) when determining chemotherapy doses, regardless of obesity status 1
- Full weight-based dosing has been shown to not increase toxicity in obese patients compared to non-obese patients and provide better disease-free and overall survival outcomes 1, 2
- The standard formula for calculating BSA is: BSA = √[(Height in cm × Weight in kg)/3600] [1]
- For example, a patient with a height of 170 cm and a weight of 84 kg would have a BSA of 1.99 m², resulting in recommended doses for AC chemotherapy of doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² 1
Special Considerations for Chemotherapy Agents
- Carboplatin should be dosed using the Calvert formula based on glomerular filtration rate (GFR), where Total dose (mg) = [AUC (target)] × [GFR + 25], and GFR should not exceed 125 mL/min in the formula 1
- Vincristine is often capped at 2 mg maximum dose when used in CHOP or CVP regimens 1
- Bleomycin is often given as a fixed dose in certain regimens 1
- The standard AC regimen consists of doxorubicin (60 mg/m² IV on day 1) and cyclophosphamide (600 mg/m² IV on day 1), cycled every 21 days for a total of 4 cycles, as recommended by the National Comprehensive Cancer Network 3, 4
Monitoring and Adjusting Doses
- Assess for toxicity using the same parameters as for non-obese patients 1
- If toxicity occurs in an obese patient with renal impairment, respond to treatment-related toxicities in the same way as for non-obese patients, and resume full weight-based doses for subsequent cycles only if the cause of toxicity has been resolved 1
- Do not use obesity status alone as a reason to maintain reduced doses after toxicity resolution 1
- Maintaining reduced doses after resolution of toxicity is not recommended, and full weight-based dosing should be resumed if the cause of toxicity (e.g., impaired renal function) has improved 1
Supportive Care and Management
- Antiemetic prophylaxis should include a combination of 5-HT3 receptor antagonist, dexamethasone, and NK1 receptor antagonist, with adjustments for drug interactions, as recommended by the American Society of Clinical Oncology and the National Comprehensive Cancer Network 5, 6
- Patients undergoing AC chemotherapy should be monitored for neutropenia, with fever requiring immediate evaluation, and consideration of G-CSF support, as recommended by the National Comprehensive Cancer Network 7
- Growth factor support (G-CSF) is mandatory for dose-dense AC regimens to prevent neutropenia, and administering AC chemotherapy every 14 days instead of every 21 days has shown improved outcomes in certain breast cancer patients 3, 4
- Immediate broad-spectrum antibiotics should be administered for neutropenic fever, with blood and urine cultures taken before starting antibiotics, and a chest X-ray if pulmonary symptoms are present, as recommended by the Journal for ImmunoTherapy of Cancer 8
- Fertility preservation options should be discussed with patients before starting treatment, and ongoing symptom management is crucial, as some side effects may persist after treatment completion 3
Cardiovascular and Thromboembolic Risk Management
- The National Comprehensive Cancer Network recommends monitoring for age-related risks, with patients aged 65 years or older at higher risk for all toxicities, and LVEF assessment before starting AC chemotherapy due to potential cardiotoxicity of doxorubicin 3, 4, 7
- The Journal of Clinical Oncology recommends assessing for thromboembolism risk at each visit, as AC chemotherapy increases the risk of venous thromboembolism, and trastuzumab should not be given concurrently with anthracyclines due to increased cardiac toxicity risk 3, 4, 9